Investor Relations

IR News

IR Latest Materials

FY2025 Third Quarter Results Briefing Session - Script
FY2025-Q3 Financial Report (Oct. 1-Dec. 31, 2025)
FY2025 Third Quarter Results Briefing Session - Material

Past materials and other documents are available in the IR Library.

IR Library

Stock Prices
Press Release E-mail Alerts

IR Calendar

IR Calendar

Management Policy
- Mid-Term Business Plan
- Disclosure Policy

Financial Information

IR Library

Stock and Shareholder Information

Development Pipeline

JCR Pharma is leveraging its proprietary biotechnology and expertise cultivated over the years to engage in the research and development of high-value-added new drugs.

Product Information

We have expanded our therapeutic portfolio through products including growth hormone therapies and treatments for mucopolysaccharidosis type II, and have obtained approvals for Japan’s first domestically developed biosimilars and allogeneic regenerative medicine products.